• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of As203-besed new chemotherapy for advanced prostate cancer

Research Project

Project/Area Number 14370514
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionKAGAWA UNIVERSITY(FACULTY OF MEDICINE)

Principal Investigator

KAKEHI Yoshiyuki  Kagawa University(Faculty of Medicine), Urology, Professor, 医学部, 教授 (20214273)

Co-Investigator(Kenkyū-buntansha) KAKIZUKA Akira  Kyoto University, Graduate School of Biostudies, Professor, 大学院・生命科学研究科, 教授 (80204329)
張 祥華  香川医科大学, 医学部, 助手 (30274286)
Project Period (FY) 2002 – 2003
Project Status Completed (Fiscal Year 2003)
Budget Amount *help
¥12,600,000 (Direct Cost: ¥12,600,000)
Fiscal Year 2003: ¥4,000,000 (Direct Cost: ¥4,000,000)
Fiscal Year 2002: ¥8,600,000 (Direct Cost: ¥8,600,000)
Keywordsarsenic trioxide / apoptosis / prostate cancer / renal cancer / buthionine sulfoximine / reactive oxveren species / 三酸化ヒ素 / buthionine sulfoximine
Research Abstract

Arsenic trioxide (As203) induces clinical remission in acute promyelocytic leukemic patients and apoptosis in various tumor cells in vitro and in vivo. The purpose of this study is to develop As203-based new chemotherapy for hormone refractory prostate cancer and advanced renal cancer. Major findings of our experiments are following ; 1)Higher concentration (10-100uM) of As203 induced apoptosis and lower concentration 0.1? 10uM) of As203 resulted in inhibition of cell growth in androgen insensitive prostate cancer PC3 and Du145 cells. 2)As203 activated p38, JNK, caspase-3 in a dose-dependent manner. 3)An anti-oxidant N-acetyl-cysteine inhibited the apoptosis induced by As203 through suppressing p38, JNK, and caspase-3 activity and ROS production. Based on the results described above, we investigated whether lower concentration of As203 could induce apoptosis by suppressing radical scavenging system. As a consequence, combination of lower concentration of As203 with L-buthionine sulfoximine (BSD) successfully induced apoptosis in prostate, renal, breast, and lung cancers in vitro but did not in normal cells (Cell Death Differ 2004).

Report

(3 results)
  • 2003 Annual Research Report   Final Research Report Summary
  • 2002 Annual Research Report
  • Research Products

    (18 results)

All Other

All Publications (18 results)

  • [Publications] Maeda H, Kakehi Y, Kakizuka ほか4名: "Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine"Cell Death Differ. (印刷中). (2004)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Wu X-X, Ogawa O, Kakehi Y: "Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine"Int J Oncol. (印刷中). (2004)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Kakehi Y, ほか5名: "Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia"Prostate. 351-356 (2004)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Taoka R, Kakehi Y, ほか3名: "Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 (MIC-1) gene in symptomatic benign prostatic hyperplasia"J Urol. 2330-2335 (2004)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Kakehi Y: "Watchful waiting as atreatment option for localized prostate cancer in the PSA era"Jpn J Clin Oncol. 33(1). 1-5 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Maeda H, Kakehi Y, Kakizuka et al.: "Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-butnionine-sulfoxiniine"Cell Death Differ. (In press). (2004)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Wu X-X, Ogawa O, Kakehi Y et al.: "Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-butnionine sulfoximine"Int J Oncol. (In press). (2004)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Kakehi Y, et al.: "Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia"Prostate. 59. 351-356 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Taoka R, Kakehi Y, et al.: "Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 (MIC-1) gene in symptomatic benign prostatic hyperplasia"J Urol. 171. 2330-2335 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Kakehi Y.: "Watchful waiting as atreatment option for localized prostate cancer in the PSA era"Jpn J Clin Oncol. 33(1). 1-5 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Maeda H, Kakehi Y, Kakizukaほか4名: "Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine"Cell Death Differ. (印刷中). (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Wu X-X, Ogawa O, Kakehi Y: "Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine"Int J Oncol. (印刷中). (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Kakehi Y, ほか5名: "Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia"Prostate. (印刷中). (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Taoka R, Kakehi Y, ほか3名: "Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 (MIC-1) gene in symptomatic benign prostatic hyperplasia"J Urol. (印刷中). (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Kakehi Y: "Watchful waiting as atreatment option for localized prostate cancer in the PSA era"Jpn J Clin Oncol. 33(1). 1-5 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Wu X-X, Kakehi Y.Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, Terachi T, Ogawa O: "Doxorubicin enhances TRAML-induced apoptosis in prostate cancer"Int J Oncol. 20. 949-954 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kakehi Y, Kamoto T, Shiraishi T Kato T, Tobisu K, Akakura K, Egawa S, Maeda O, Sumiyoshi Y, Arai Y, Ogawa O: "Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men"Eur Urol. 41. 47-53 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Maeda H, Hori S, Nishitoh H, Ogawa O, Kakehi Y, Kakizuka A: "Tumor growth inhibition by arsenic trioxide (As2O3)in the orthotopic metastasis model of androgen-independent prostate cancer"Cancer Res. 61. 5432-5440 (2001)

    • Related Report
      2002 Annual Research Report

URL: 

Published: 2002-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi